The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD).
 
Mitchell Elliott
No Relationships to Disclose
 
Jesús Fuentes Antrás
No Relationships to Disclose
 
Philippe Echelard
No Relationships to Disclose
 
Nicholas Meti
Honoraria - Novartis; Takeda
Consulting or Advisory Role - AstraZeneca; Pfizer; Seagen; Takeda
Travel, Accommodations, Expenses - Novartis Canada Pharmaceuticals Inc
 
Alisa Nguyen
No Relationships to Disclose
 
Michelle Liu
No Relationships to Disclose
 
Carolina Sanabria Salas
No Relationships to Disclose
 
Christopher Gareth Smith
Employment - NeoGenomics Laboratories
 
Moira Katherine Rushton
Honoraria - Gilead Sciences; Lilly; Novartis; Pfizer
Consulting or Advisory Role - Novartis; Pfizer; Viatris
Speakers' Bureau - AstraZeneca; Lilly
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Hookipa Pharma; InterRNA; Janpix; Janssen; Merck; Navire; Oncorus; Relay Therapeutics; Roche; Sanofi; Seagen; Tessa Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
Hal K. Berman
No Relationships to Disclose
 
Philippe L. Bedard
Consulting or Advisory Role - Amgen; BMS (Inst); Gilead Sciences; Lilly; Merck; Pfizer (Inst); Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
 
David W. Cescon
Consulting or Advisory Role - AstraZeneca; Eisai; Gilead Sciences; GlaxoSmithKline; INFLEX; Lilly; Merck; Novartis; Pfizer; SAGA Diagnostics
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Knight Therapeutics (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent (US62/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene.
Expert Testimony - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Inivata